Scisparc Ltd (SPRC)

Aug 18, 2026, 8:06 AM EDT - 1 day ago

SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million

Aug 17, 2026, 9:10 PM EDT - 1 day ago

Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement

Aug 12, 2026, 5:00 PM EDT - 6 days ago

NeuroThera Labs Inc. Closes First Tranche Of Non-Brokered Private Placement

Aug 12, 2026, 8:25 AM EDT - 7 days ago

SciSparc's Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

Aug 12, 2026, 8:02 AM EDT - 7 days ago

NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

Aug 5, 2026, 8:22 AM EDT - 14 days ago

SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

Aug 5, 2026, 8:05 AM EDT - 14 days ago

NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome

Jul 31, 2026, 8:20 AM EDT - 19 days ago

SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics

2026-07-29T14:00:47.000Z - 20 days ago

Scisparc Ltd trading resumes

2026-07-29T13:56:02.000Z - 20 days ago

Scisparc Ltd trading halted, volatility trading pause

Jul 29, 2026, 8:32 AM EDT - 21 days ago

SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company

2026-07-27T13:16:01.000Z - 23 days ago

SciSparc to target agentic artificial intelligence market

Jul 27, 2026, 8:25 AM EDT - 23 days ago

SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity

2026-07-15T13:06:01.000Z - 5 weeks ago

SciSparc initiates SCI-110 clinical trial in Germany

Jul 15, 2026, 8:41 AM EDT - 5 weeks ago

SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

Jul 15, 2026, 8:31 AM EDT - 5 weeks ago

NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

TS

Jul 2, 2026, 5:30 PM EDT - 6 weeks ago

NeuroThera Labs Announces Upsize to Private Placement

Jun 30, 2026, 6:00 PM EDT - 7 weeks ago

NeuroThera Labs Announces C$5,000,000 Private Placement of Units

Jun 4, 2026, 7:32 AM EDT - 2 months ago

SciSparc: Subsidiary NeuroThera Labs Completed Acquisition of CliniQuantum

Jun 3, 2026, 5:15 PM EDT - 2 months ago

Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd.

May 28, 2026, 8:40 AM EDT - 2 months ago

SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum

May 20, 2026, 5:00 PM EDT - 3 months ago

Neurothera Labs Announces Adoption of Semi-Annual Reporting

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Neurothera Labs Announces Continuance into Ontario

Apr 23, 2026, 6:00 PM EDT - 4 months ago

Neurothera Labs Engages bullVestor for Investor Relations Activities

2026-03-16T12:25:23.000Z - 5 months ago

SciSparc discloses patent application for depression yherapy

Mar 16, 2026, 8:20 AM EDT - 5 months ago

SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

2026-03-12T12:01:25.000Z - 5 months ago

SciSparc’s Neurothera Labs announces publication of international patent

CMND

Mar 12, 2026, 7:55 AM EDT - 5 months ago

SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

2026-03-10T13:38:10.000Z - 5 months ago

SciSparc says Neurothera Labs agrees to acquire majority stake in CliniQuantum

Mar 10, 2026, 9:28 AM EDT - 5 months ago

SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails

Mar 10, 2026, 8:59 AM EDT - 5 months ago

Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

CMND

Mar 10, 2026, 7:30 AM EDT - 5 months ago

Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd.

2026-03-04T00:50:09.000Z - 6 months ago

Scisparc Ltd trading halted, news pending

2026-03-02T13:35:06.000Z - 6 months ago

SciSparc announces 1-for-9 reverse share split

2026-03-02T13:28:37.000Z - 6 months ago

SciSparc announces 1-for-9 reverse share split

2026-03-02T13:23:28.000Z - 6 months ago

SciSparc announces 1-for-9 reverse share split

Mar 2, 2026, 8:00 AM EST - 6 months ago

SciSparc Announces 1-for-9 Reverse Share Split

2026-02-17T22:30:16.000Z - 6 months ago

SciSparc files to sell 23.04M ordinary shares for holders

2026-02-03T21:40:29.000Z - 7 months ago

SciSparc files $50M mixed securities shelf

2026-02-02T13:36:11.000Z - 7 months ago

SciSparc says Neurothera Labs granted U.S. patent for cannabinoid tech

Feb 2, 2026, 8:24 AM EST - 7 months ago

SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

Feb 2, 2026, 8:00 AM EST - 7 months ago

Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA

2026-01-26T13:20:59.000Z - 7 months ago

SciSparc completes acquisition of IP portfolio of patents, trademarks

Jan 26, 2026, 8:13 AM EST - 7 months ago

SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization

2026-01-13T12:00:18.000Z - 7 months ago

SciSparc to acquire a treasury of patents for the endoscope market

Jan 13, 2026, 6:55 AM EST - 7 months ago

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

2026-01-12T21:11:27.000Z - 7 months ago

SciSparc receives noncompliance notification from Nasdaq

Jan 12, 2026, 4:02 PM EST - 7 months ago

SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Jan 8, 2026, 6:00 PM EST - 7 months ago

Neurothera Labs Announces Results of AGM

Dec 30, 2025, 8:17 AM EST - 8 months ago

SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Dec 30, 2025, 8:00 AM EST - 8 months ago

Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects

Dec 2, 2025, 9:29 AM EST - 9 months ago

SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 2, 2025, 8:05 AM EST - 9 months ago

Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Dec 1, 2025, 8:32 AM EST - 9 months ago

SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio

Nov 26, 2025, 7:38 AM EST - 9 months ago

SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems

Nov 20, 2025, 6:42 AM EST - 9 months ago

SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

Nov 19, 2025, 8:30 AM EST - 9 months ago

Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression

CMND

Oct 24, 2025, 7:55 AM EDT - 10 months ago

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 23, 2025, 4:03 PM EDT - 10 months ago

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Oct 23, 2025, 8:55 AM EDT - 10 months ago

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Oct 22, 2025, 3:30 PM EDT - 10 months ago

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

Oct 20, 2025, 7:41 AM EDT - 10 months ago

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Oct 15, 2025, 7:05 AM EDT - 11 months ago

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 6, 2025, 6:40 AM EDT - 11 months ago

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

Sep 29, 2025, 4:03 PM EDT - 11 months ago

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Sep 25, 2025, 7:05 AM EDT - 11 months ago

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

Aug 28, 2025, 9:24 AM EDT - 1 year ago

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc